July 19, 2024
Top-line Data on RESTORE Study of Optogenetic Therapy for Retinitis Pigmentosa Presented at ASRS
Thirty percent of patients maintained 3-line vision gain.
2024 American Society of Retina Specialists Annual Meeting
Related Articles
July 18, 2024
TEASE-3 Study Data on Oral Therapy for Stargardt Disease Presented at ASRS
Younger, asymptomatic siblings of Stargardt patients maintained vision.
July 18, 2024
Interim Phase 1 HELIOS Trial Data of Axpaxli for NPDR Presented at ASRS
The axitinib implant demonstrated both safety and efficacy.
July 17, 2024
Phase 2 PRISM Trial Data on 4D-150 Gene Therapy Presented at 2024 ASRS Meeting
Patients showed a durable improvement of vision with 93% remaining injection free.
July 17, 2024
Supplemental Injection Data From DAVIO 2 Trial of EYP-1901 Presented at ASRS
Two-thirds of eyes remained supplement free.
July 17, 2024
Outcomes of Faricimab in DME Study Presented at ASRS
Data from the RHONE-X extension trial, presented for the first time at the meeting, show that Vabysmo maintained safety and efficacy over 4 years.